An open-label, dose-escalation study to evaluate the safety and pharmacokinetics of CEP-9722 (a PARP-1 and PARP-2 inhibitor) in combination with gemcitabine and cisplatin in patients with advanced solid tumors

No abstract is available for this paper.

• Publication year

  2016

• Venue

  Anti-Cancer Drugs

• Publication date

  2016-04-01

• Fields of study

  Medicine

• Identifiers
  DOI 10.1097/CAD.0000000000000336PMID 26796987
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Olaparib combined with chemotherapy for recurrent platinum-sensitive ovarian cancer: a randomised phase 2 trial.

  2015cited by this paper
• Olaparib monotherapy in patients with advanced cancer and a germline BRCA1/2 mutation.

  2015cited by this paper
• Differential Potential of Pharmacological PARP Inhibitors for Inhibiting Cell Proliferation and Inducing Apoptosis in Human Breast Cancer Cells

  2015cited by this paper
• Olaparib maintenance therapy in patients with platinum-sensitive relapsed serous ovarian cancer: a preplanned retrospective analysis of outcomes by BRCA status in a randomised phase 2 trial.

  2014cited by this paper
• Phase 1 dose-escalation study of the PARP inhibitor CEP-9722 as monotherapy or in combination with temozolomide in patients with solid tumors

  2014cited by this paper
• A Phase I Combination Study of Olaparib with Cisplatin and Gemcitabine in Adults with Solid Tumors

  2012cited by this paper
• Phase I study of PARP inhibitor ABT-888 in combination with topotecan in adults with refractory solid tumors and lymphomas.

  2011cited by this paper
• PARP inhibitors in cancer therapy: two modes of attack on the cancer cell widening the clinical applications.

  2009cited by this paper
• The selective poly(ADP-ribose) polymerase-1(2) inhibitor, CEP-8983, increases the sensitivity of chemoresistant tumor cells to temozolomide and irinotecan but does not potentiate myelotoxicity

  2007cited by this paper
• Combination therapy of poly (ADP‐ribose) polymerase inhibitor 3‐aminobenzamide and gemcitabine shows strong antitumor activity in pancreatic cancer cells

  2006cited by this paper
• Chemopotentiation of temozolomide, irinotecan, and cisplatin activity by CEP-6800, a poly(ADP-ribose) polymerase inhibitor.

  2003cited by this paper
• The response of Parp knockout mice against DNA damaging agents.

  2000cited by this paper
• Potentiation of temozolomide and topotecan growth inhibition and cytotoxicity by novel poly(adenosine diphosphoribose) polymerase inhibitors in a panel of human tumor cell lines.

  2000cited by this paper

• Clinical outcomes of DNA-damaging agents and DNA damage response inhibitors combinations in cancer: a data-driven review

  2025cites this paper
• The combination therapy of isomucronulatol 7-O-beta-glucoside (IMG) and CEP-9722 targeting ferroptosis-related biomarkers in non-small cell lung cancer (NSCLC)

  2023cites this paper
• Design and Activity of Novel Oxadiazole Based Compounds That Target Poly(ADP-ribose) Polymerase

  2022cites this paper
• Small molecules in targeted cancer therapy: advances, challenges, and future perspectives

  2021cites this paper
• Inhibition of DNA Repair in Cancer Therapy: Toward a Multi-Target Approach

  2020cites this paper
• Targeting the DNA damage response for patients with lymphoma: Preclinical and clinical evidences.

  2020cites this paper
• Overview of New Treatments with Immunotherapy for Breast Cancer and a Proposal of a Combination Therapy

  2020influential citation
• PARP inhibitors: clinical development, emerging differences, and the current therapeutic issues

  2019cites this paper
• Synthetic Lethality of PARP Inhibition and Ionizing Radiation is p53-dependent

  2018cites this paper
• PARP inhibitors as antitumor agents: a patent update (2013-2015)

  2017cites this paper
• PARP inhibitors as precision medicine for cancer treatment

  2017cites this paper
• An Update on Poly(ADP-ribose)polymerase-1 (PARP-1) Inhibitors: Opportunities and Challenges in Cancer Therapy.

  2016cites this paper